HER3 mediates acquired resistance to HER2-targeted therapy in esophageal adenocarcinoma

被引：1
|
作者：
Ebbing, Eva A. [1 ]
Medema, Jan Paul [1 ]
Meijer, Sybren L. [1 ]
Krishnadath, Kausilia K. [1 ]
Henegouwen, Mark I. van Berge [1 ]
Bijlsma, Maarten F. [1 ]
van Laarhoven, Hanneke W. M. [1 ]
机构：
[1] AMC, Amsterdam, Netherlands
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-350
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
350
引用
收藏
页数：1
相关论文
共 50 条
  • [41] EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer
    Fichter, Christiane Daniela
    Timme, Sylvia
    Braun, Julia Alexandra
    Gudernatsch, Verena
    Schoepflin, Anja
    Bogatyreva, Lioudmilla
    Geddert, Helene
    Faller, Gerhard
    Klimstra, David
    Tang, Laura
    Hauschke, Dieter
    Werner, Martin
    Lassmann, Silke
    INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (07) : 1517 - 1530
  • [42] Cardiotoxicity of HER2-targeted therapies
    Copeland-Halperin, Robert S.
    Liu, Jennifer E.
    Yu, Anthony F.
    CURRENT OPINION IN CARDIOLOGY, 2019, 34 (04) : 451 - 458
  • [43] HER2-targeted therapy in colorectal cancer: a comprehensive review
    Benli, Yeliz
    Arikan, Helin
    Akbulut-caliskan, Ozge
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [44] HER2-targeted Tumor immunotherapy
    Wei, Huafeng
    Guo, Yajun
    BIOMEDICINE & PHARMACOTHERAPY, 2009, 63 (05) : 325 - 325
  • [45] Late cardiotoxicity related to HER2-targeted cancer therapy
    Isabelle Senechal
    Maria Sol Andres
    Jieli Tong
    Ylenia Perone
    Sivatharshini Ramalingam
    Muhummad Sohaib Nazir
    Stuart D Rosen
    Nicholas Turner
    Alistair Ring
    Alexander R Lyon
    Cardio-Oncology, 10
  • [46] The gut microbiota contributes to the effectiveness of HER2-targeted therapy
    Di Modica, Martina
    Regondi, Viola
    Gargari, Giorgio
    Bonizzi, Arianna
    Arioli, Stefania
    Belmonte, Beatrice
    Tripodo, Claudio
    Guglielmetti, Simone
    Corsi, Fabio
    Triulzi, Tiziana
    Tagliabue, Elda
    CANCER RESEARCH, 2019, 79 (13)
  • [47] Truncated HER2: implications for HER2-targeted therapeutics
    Zagozdzon, Radoslaw
    Gallagher, William M.
    Crown, John
    DRUG DISCOVERY TODAY, 2011, 16 (17-18) : 810 - 816
  • [48] Recent advances in HER2-targeted delivery for cancer therapy
    Dhritlahre, Rakesh Kumar
    Saneja, Ankit
    DRUG DISCOVERY TODAY, 2021, 26 (05) : 1319 - 1329
  • [49] Loss of HER2 after HER2-targeted treatment
    Ignatov, Tanja
    Gorbunow, Franceska
    Eggemann, Holm
    Ortmann, Olaf
    Ignatov, Atanas
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (02) : 401 - 408
  • [50] Loss of HER2 after HER2-targeted treatment
    Tanja Ignatov
    Franceska Gorbunow
    Holm Eggemann
    Olaf Ortmann
    Atanas Ignatov
    Breast Cancer Research and Treatment, 2019, 175 : 401 - 408
12345